Condition: Papillary-Only Non-muscle-invasive Bladder Cancer · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
This is a multicenter, randomized, Double-blind phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus Placebo Combined with BCG in patients with high-risk BCG-naive Papillary-Only non-muscle-invasive bladder cancer (NMIBC)
This description comes directly from the study's public registry record.
Wenliang Wang · 0518-82342973 · wenliang.wang@hengrui.com
Qi Zhang · 021-60453139 · qi.zhang@hengrui.com
Always discuss trial participation with your own doctor first.
| The First Medical Center of the Chinese People's Liberation Army General Hospital | Beijing, Beijing Municipality, China | — |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07726992